Biotech Cnbc Disappointing Gilead Hammered Hepatitis Mody Seema
Gilead Sciences shares are getting hammered today after disappointing test results on one of its Hepatitis C drugs, with CNBC's Seema Mody. (CNBC)
MSNBC | February 17, 2012
Tags:. .seema. .gilead. .mody. .biotech. .hepatitis